Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.71 |
| ▸ | CTSS | P25774 | 4/20 | 0.42 |
| ▸ | CTSV | O60911 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4221335 | 1.00 | CTSK (0.71) | CTSKCTSSCTSVCTSLCACNA1B | |
| SCHEMBL4221341 | 1.00 | CTSK (0.71) | CTSKCTSSCTSVCTSLCACNA1B | |
| SCHEMBL5941412 | 1.00 | CTSK (0.71) | CTSKCTSSCTSVCTSLCACNA1B | |
| SCHEMBL4039552 | 0.99 | CTSK (0.72) | CTSKCTSSCTSVCTSLCACNA1B | |
| SCHEMBL4043707 | 0.92 | CTSK (0.60) | CTSKCTSSCTSVCTSLCACNA1B | |
| SCHEMBL4045280 | 0.91 | CTSK (0.61) | CTSKCTSSCTSVCTSLCACNA1B | |
| SCHEMBL4037924 | 0.91 | CTSK (0.59) | CTSKCTSSCTSVCTSLCACNA1B | |
| SCHEMBL4046015 | 0.90 | CTSK (0.60) | CTSKCTSSCTSVCTSLCACNA1B | |
| SCHEMBL5941558 | 0.90 | CTSK (0.78) | CTSKCTSSCTSVCTSLCCR1 | |
| SCHEMBL4224342 | 0.90 | CTSK (0.78) | CTSKCTSSCTSVCTSLCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1678157-A4 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | REDDY US THERAPEUTICS INC (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-7456288-B2 | Heterocyclic compounds and methods of making and using thereof | REDDY US THERAPEUTICS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1678157-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | Reddy US Therapeutics, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| US-20050119269-A1 | Heterocyclic compounds and methods of making and using thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-02 | — | — | US | disclosed |
| WO-2005042712-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | REDDY US THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005040163-A1 | HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE) | DR. REDDY'S LABORATORIES LTD (IN) | 2005-05-06 | — | — | WO | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885CTSS 3/4885CTSV 29/4885 |
| US-20050119269-A1 | Heterocyclic compounds and methods of making and using thereof | PYGM, MYLK, HMOX1 | CTSK 1474/4885CTSS 1653/4885CTSV 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.